Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Krause

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
The British Journal of Ophthalmology|October 15, 2020
Pellucid marginal degeneration versus keratoconus: distinction with wide-field SD-OCT corneal sublayer pachymetryNiklas Mohr, Mehdi Shajari, Daniel Krause, et al.
Scientific Reports|November 10, 2020
Comparison of variables measured with a Scheimpflug device for evaluation of progression and detection of keratoconusSophie Neuhann, Anna Schuh, Daniel Krause, et al.
Life (Basel, Switzerland)|November 27, 2025
High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?Caspar Liesenhoff, Carolin Meyrl, Daniel Krause, et al.
Plos Genetics|June 23, 2021
LAMP3 deficiency affects surfactant homeostasis in miceLars P Lunding, Daniel Krause, Guido Stichtenoth, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
The British Journal of Ophthalmology|October 15, 2020
Pellucid marginal degeneration versus keratoconus: distinction with wide-field SD-OCT corneal sublayer pachymetryNiklas Mohr, Mehdi Shajari, Daniel Krause, et al.
Scientific Reports|November 10, 2020
Comparison of variables measured with a Scheimpflug device for evaluation of progression and detection of keratoconusSophie Neuhann, Anna Schuh, Daniel Krause, et al.
Life (Basel, Switzerland)|November 27, 2025
High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?Caspar Liesenhoff, Carolin Meyrl, Daniel Krause, et al.
Plos Genetics|June 23, 2021
LAMP3 deficiency affects surfactant homeostasis in miceLars P Lunding, Daniel Krause, Guido Stichtenoth, et al.
Pageof 4